FDA Drug Application (202171) for LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE by MATRIX LABS LTD

Back to FDA Applications sponsored by MATRIX LABS LTD

Application Number202171
Product Number001
FormTABLET; ORAL
Dosage300MG; 300MG; 200MG
Product Market Status Tentative Approval
Therapeutic Equivalence Evaluation Code
Reference Drug
Drug NameLAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Active IngredientLAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE



Back to FDA Applications sponsored by MATRIX LABS LTD

Problems, Comments, Suggestions? Click here to contact Greg Thatcher

Please read my Disclaimer





Copyright (c) 2013 Thatcher Development Software, LLC. All rights reserved. No claim to original U.S. Gov't works.